MacroGenics reported $46.62M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Daiichi Sankyo JPY 1.58T 44.86B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Genmab DKK 5.3B 6M Jun/2025
Geron USD 259.53M 8.71M Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
MacroGenics USD 46.62M 69.44M Jun/2025
Merck USD 49.06B 725M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Xencor USD 620.35M 19.52M Jun/2025